APOO

APOO encodes MIC26, a 22 kDa inner mitochondrial membrane protein that functions as a subunit of the MICOS (mitochondrial contact site and cristae organizing system) complex, where it is essential for crista junction formation, respiratory chain supercomplex integrity, and mitochondrial ultrastructure. MIC26 physically interacts with MIC60, MIC27, and MIC10, destabilizes MIC10 oligomers (opposite to MIC27), and cooperates with MIC27 to maintain cardiolipin levels, F1Fo-ATP synthase assembly, and oxidative phosphorylation capacity (PMID:25764979, PMID:29733859, PMID:32788226). Tissue-specific deletion in brown adipocytes impairs thermogenesis and shifts metabolism from oxidative to glycolytic, while macrophage-specific loss reduces OPA1, increases mitochondrial fission, and enhances efferocytosis (PMID:37088120, PMID:37995600). Pathogenic mutations in APOO (I117T, E178*) impair MIC26 import or stability, disrupt MICOS assembly and cristae architecture, and cause mitochondrial disease (PMID:32439808, PMID:37649161).

1. 2006 Medium

   The initial characterization identified APOO as a novel apolipoprotein promoting cholesterol efflux, localizing to lipid droplets, and bearing a chondroitin sulfate chain — establishing a secreted lipoprotein identity that would later be revised.

   Evidence Confocal immunofluorescence with perilipins, chondroitinase treatment, MTP inhibitor experiments, and cholesterol efflux assays in macrophages

   PMID:16956892

   Open questions at the time

   • Lipid-droplet localization and secreted isoform identity were later shown to reflect nonspecific antibody signal
   • No mitochondrial function assessed
   • Cholesterol efflux mechanism not delineated
2. 2015 High

   Discovery that MIC26 is a bona fide MICOS subunit that spans the inner mitochondrial membrane, physically interacts with MIC60/MIC27/MIC10, and is required for crista junction maintenance and mitochondrial respiration — fundamentally redefining the gene's primary function from secreted apolipoprotein to mitochondrial structural protein.

   Evidence Reciprocal co-immunoprecipitation with MICOS subunits; miRNA knockdown with rescue; electron microscopy of cristae; respiration assays in human cells

   PMID:25764979 PMID:26217776

   Open questions at the time

   • Mechanism by which MIC26 and MIC27 antagonistically regulate each other's levels was not resolved
   • Role of cardiolipin in MIC26 function not yet addressed
   • No in vivo or organism-level data
3. 2018 Medium

   MIC26 was shown to destabilize MIC10 oligomers, functioning antagonistically to MIC27 which stabilizes them — revealing opposing regulatory roles of the two lipid-binding MICOS subunits in controlling the oligomeric state of the membrane-bending MIC10 subunit.

   Evidence Blue-native PAGE analysis of MIC10 oligomeric state in yeast and mammalian cells with MIC26/MIC27 deletion

   PMID:29733859

   Open questions at the time

   • Structural basis for opposing effects on MIC10 oligomerization unknown
   • Functional consequence of altered MIC10 oligomeric state on crista morphology not directly tested in this study
   • Single lab findings
4. 2020 High

   Combined loss of MIC26 and MIC27 demonstrated their cooperative requirement for cardiolipin homeostasis, respiratory chain supercomplex stability, and F1Fo-ATP synthase assembly — with cardiolipin synthase overexpression rescuing supercomplex defects, establishing cardiolipin as the key mediator.

   Evidence Double-KO human cells; complexome profiling; STED nanoscopy; BN-PAGE; cardiolipin synthase overexpression rescue

   PMID:32788226

   Open questions at the time

   • Direct mechanism by which MIC26/MIC27 maintain cardiolipin levels not identified
   • Whether MIC26 has lipid-binding or lipid-transfer activity is unresolved
5. 2020 High

   Identification of a pathogenic I117T missense mutation in APOO established MIC26 as a disease gene, showing the mutation impairs protein import into the inner membrane and disrupts MICOS assembly and crista junctions, with conserved phenotypes in yeast and Drosophila orthologs.

   Evidence Patient fibroblast studies; whole-exome sequencing; protein import assays; electron microscopy; cross-species KO models

   PMID:32439808

   Open questions at the time

   • Full clinical spectrum of APOO-related mitochondrial disease not delineated
   • Whether the import defect reflects a direct chaperone interaction or membrane insertion failure is unclear
6. 2023 High

   Definitive resolution of the isoform controversy: MIC26 exists exclusively as a 22 kDa mitochondrial protein; the previously reported 55 kDa secreted glycoprotein isoform was an antibody artifact, established across four cell lines, four antibodies, and mass spectrometry of the misidentified band.

   Evidence CRISPR KO in four human cell lines; multiple antibodies; tagged overexpression; glycosylation site mutagenesis; mass spectrometry

   PMID:37279200

   Open questions at the time

   • The earlier cholesterol efflux phenotype has not been re-evaluated in light of the isoform correction
   • Whether any non-mitochondrial MIC26 function persists under physiological conditions is unresolved
7. 2023 Medium

   A second pathogenic mutation (E178*) confirmed the disease relevance and showed that even correctly localized but unstable MIC26 fails to rescue cristae architecture, demonstrating that steady-state protein levels are critical for function.

   Evidence Patient exome sequencing; protein stability assays; co-IP; electron microscopy in KO rescue cells

   PMID:37649161

   Open questions at the time

   • Single-family study; broader genotype-phenotype correlation not yet available
   • Whether degradation is proteasome- or mitochondrial-protease-mediated is unknown
8. 2023 Medium

   Tissue-specific KO studies revealed that MIC26 loss in adipocytes impairs thermogenesis and shifts metabolism to glycolysis via disrupted oxidative phosphorylation and PPARα-dependent peroxisomal biogenesis, while macrophage-specific loss reduces OPA1, increases fission, and enhances efferocytosis — extending MIC26 function to whole-organism metabolic physiology.

   Evidence Adipocyte-specific and macrophage-specific KO mice; electron microscopy; OXPHOS and metabolic flux analysis; cold exposure; OPA1 rescue experiments; in vivo efferocytosis assay

   PMID:37088120 PMID:37995600

   Open questions at the time

   • Direct molecular link between MIC26 loss and OPA1 reduction not identified
   • Whether PPARα pathway involvement is direct or secondary to OXPHOS impairment is unclear
   • In vivo cardiovascular or disease relevance of efferocytosis phenotype not tested

• Key unresolved questions include the structural basis of MIC26 within the MICOS complex, whether MIC26 directly binds or transfers cardiolipin, and the full clinical spectrum of APOO-associated mitochondrial disease.
• No high-resolution structure of MIC26 within MICOS exists
• No direct lipid-binding assay for MIC26 has been reported
• Genotype-phenotype correlation across APOO mutations remains limited to two families